

ERRATUM

Open Access



Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury

Flora M. Hammond^{1*}, David N. Alexander², Andrew J. Cutler³, Stephen D'Amico⁴, Rachele S. Doody⁵, William Sauve⁶, Richard D. Zorowitz⁷, Charles S. Davis⁸, Paul Shin⁹, Fred Ledon⁹, Charles Yonan⁹, Andrea E. Formella⁹ and Joao Siffert⁹

Erratum

After publication of the original article [1], the authors noticed that there were errors in the caption of Fig. 3, and the y-axis of Fig. 6 itself.

The following statement should not have been included in the caption of Fig. 3: "CNS-LS scores were not normalized." The CNS-LS is a rank-order scale, and is not normalized. This statement was included erroneously and the authors intended on removing it prior to resubmission, but this was unfortunately overlooked.

Similarly, the y-axis within Fig. 6 was mislabelled. The CNS-LS scale ranges from 7 to 35, so the y-axis for Fig. 6 should start at a base score of 7 and not zero. The correct and updated version of Fig. 6, in which the data presented remain accurate and are unchanged, is published in this erratum.

Author details

¹Physical Medicine and Rehabilitation, Indiana University School of Medicine, Rehabilitation Hospital of Indiana, 4141 Shore Drive, Indianapolis, IN 46254, USA. ²University of California, Los Angeles, CA, USA. ³Florida Clinical Research Center, LLC, Bradenton, FL, USA. ⁴Cornerstone Medical Group, Franklin, TN, USA. ⁵Baylor College of Medicine, Houston, TX, USA. ⁶TMS NeuroHealth Centers, Richmond, VA, USA. ⁷MedStar National Rehabilitation Network, Washington, DC, USA. ⁸CSD Biostatistics, Inc., Tucson, AZ, USA. ⁹Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA.

Published online: 02 September 2016


* Correspondence: Flora.hammond@rhin.com

¹Physical Medicine and Rehabilitation, Indiana University School of Medicine, Rehabilitation Hospital of Indiana, 4141 Shore Drive, Indianapolis, IN 46254, USA

Reference

1. Hammond FM, Alexander DN, Cutler AJ, D'Amico S, Doody RS, Sauve W, et al. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. *BMC Neurol.* 2016;16:89. doi:10.1186/s12883-016-0609-0.

PRISM II: Mean CNS-LS Scores Across DM/Q Studies for PBA in Diverse Neurologic Conditions



*DM/Q 30/30 mg twice daily; this dose is not FDA-approved; [†]DM/Q 20/10 mg twice daily. [‡]Improvement from baseline in mean CNS-LS (SE).

99-AVR-102 (4 week study): End of study= mean of CNS-LS scores for Days 15 and 29; $P=0.001$ vs. controls.

02-AVR-106 (12 week DBPC study): End of study= mean of CNS-LS scores on Days 15, 29, 57, and 85; $P<0.0001$ vs. placebo.

07-AVR-123 (12 week DBPC study): End of study is Week 12 intent to treat; $P<0.05$ vs. placebo.

PRISM II: End of study is at Day 90/Final Visit; $P<0.001$ vs. baseline

Fig. 6 Mean CNS-LS Scores Across DM/Q Studies for PBA Secondary to Diverse Neurologic Conditions. *DM/Q 30/30 mg twice daily; [†]DM/Q 20/10 mg twice daily. [‡]Improvement from baseline in mean CNS-LS (SE). 99-AVR-102 (4 week study comparing DM/Q to DM or Q monotherapy): End of study is the mean of the CNS-LS scores for Days 15 and 29; $P=0.001$ vs. dextromethorphan comparator and $P<0.001$ vs. quinidine comparator. 02-AVR-106 (12 week DBPC study): End of study is the mean of the CNS-LS scores on Days 15, 29, 57, and 85; $P<0.0001$ vs. placebo. 07-AVR-123 (12 week DBPC study): End of study is at Week 12 intent to treat; $P<0.05$ vs. placebo. PRISM II: End of study is at Day 90/Final Visit; $P<0.001$ vs. baseline in all 3 cohorts. ALS = amyotrophic lateral sclerosis; CNS-LS = Center for Neurologic Study–Lability Scale; DM/Q = dextromethorphan/quinidine; MS = multiple sclerosis; PBA = pseudobulbar affect; TBI = traumatic brain injury; SE = standard error